From San Diego’s Regulus Therapeutics Readies for IPO This Week:

Nasdaq 300x200 (courtesy Nasdaq)

Nasdaq 300×200 (courtesy Nasdaq)—

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
What’s Next in Neuroscience Therapies
New approaches & tech are on the horizon that could change how researchers and clinicians approach brain and neurological disorders

Sponsored · Whitepaper
The Importance of Early Key Opinion Leader Outreach in the Biologics & Biosimilars Marketplace
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson

Sponsored · Whitepaper
Potency Assay Development for Cell and Gene Therapy Products
Create well-controlled, biologically relevant test systems and validate them to support FDA approvals
Absorption Systems

Xconomy on Demand

We offer a number of ways to subscribe for free!